AstraZeneca Plans to Invest $50 Billion in U.S. by 2030
Plans include a proposal for a new drug substance manufacturing center focused on weight-loss drugs
- AstraZeneca plans to invest $50 billion in the U.S. by 2030, including a new drug substance manufacturing center.
- The Virginia facility would be AstraZeneca’s largest single manufacturing investment in the world.
- The investment aims to boost research-and-development, expanding facilities in Maryland and Massachusetts.
AstraZeneca AZN -0.60%decrease; red down pointing triangle said it plans to invest $50 billion in the U.S. by 2030, marking the latest drugmaker to commit to American manufacturing as looming tariffs threaten to raise costs across the industry.
The biopharmaceutical giant said Monday the investment includes plans for a new drug substance manufacturing center focused on chronic diseases. The multibillion-dollar facility would produce drug substances for the company’s weight-management and metabolic portfolio, including oral GLP-1s.
The Virginia facility would be AstraZeneca’s largest single manufacturing investment in the world, the company said.
Other drugmakers such as Eli Lilly LLY -1.23%decrease; red down pointing triangle & Co., Roche Holding ROG -1.12%decrease; red down pointing triangle, Regeneron Pharmaceuticals REGN 0.55%increase; green up pointing triangle and Merck MRK -0.81%decrease; red down pointing triangle & Co. have similarly committed billions to expand their U.S. manufacturing efforts in recent months.
The planned investments come as President Trump threatens to impose tariffs of up to 200% on pharmaceuticals made abroad. Companies would be given a runway of up to a year and a half to reshore supply chains before the levies come into effect, Trump said earlier this month.
Commerce Secretary Howard Lutnick said Trump’s new tariff policies are focused on ending the U.S.’s reliance on foreign supply of key pharmaceutical products. “We are proud that AstraZeneca has made the decision to bring substantial pharmaceutical production to our shores,” Lutnick said.
The U.K. company’s planned investment also aims to prop up its research-and-development efforts, expanding a facility in Gaithersburg, Md., and building a new center in Cambridge, Mass.
It would also add manufacturing facilities for cell therapy in Rockville, Md., and Tarzana, Calif., and expand manufacturing in Mount Vernon, Ind., and Coppell, Texas, AstraZeneca said.
Chief Executive Pascal Soriot said the investment would support AstraZeneca’s goal of $80 billion in revenue by 2030. It is also expected to create tens of thousands of new jobs across U.S., the company said.